重组人血管内皮抑制素联合化疗治疗24例晚期肺腺癌的临床研究

目的：观察重组人血管内皮抑制素联合化疗治疗晚期肺腺癌的疗效和不良反应。方法：24例Ⅲ～Ⅳ期肺腺癌患者接受重组人血管内皮抑制素与化疗的联合治疗,按照RECIST标准每2周期后评价疗效和生活质量评分,按照NCI CTC 3.0每周期后评价毒性。结果：有24例患者可以评价客观疗效及不良反应评价。PR 6例,SD 16例,PD 2例,RR 25%（6/24）,DCR 91.7%（22/24）;生活质量改善9例（37.5%）,稳定10例（41.7%）,5例下降（20.8%）。3/4级不良反应包括白细胞下降6例（25%）,血小板下降3例（12.5%）。另外有3例（12.5%）出现恶心、呕吐。结论：重组人血管内皮抑制素与化疗联合应用能改善和稳定晚期肺腺癌患者的生存和生活质量,不良反应低,安全性好,值得临床进一步深入观察。

Endostar combined with chemotherapy on 24 cases of advanced adenocarcinoma lung cancer

Objective： To observe prospectively and systematically the efficacy and safety of endostatin injection（YH-16,Endostar）,a new molecular targeted anti-tumor agent,combined with the chemotherapy on 24 cases of advanced adenocarcinoma lung cancer.Methods： Endostar combined with chemotherapy were administrated to 24 cases of advanced adenocarcinoma lung cancer of stage Ⅲ-Ⅳconfirmed by histopathology or cytopathology.The efficacy was evaluated strictly after 2 cycles according to RECIST criteria,and quality of life（QOL）was evaluated according to Karnofsky scores.Otherwise safety was evaluated after 1 cycle according to NCI CTC 310 version criteria.Results：Twenty-four cases were evaluable for efficacy and capable of safety evaluation.Among 24 evaluable cases,there were 6 cases achieved PR,16 cases of SD,and 2 cases of PD.The objective response rate（RR）was 25%（6 /24）,the disease control rate（DCR）was 91.7%（22 /24）.The quality of life（QOL）were improved on 9 cases（37.5%）,stabled on 10 cases（41.7%）,and decreased on 5 cases（20.8%）.The occurrence rates of G3 /4 toxicities were low,including neutropenia（6/24,25%）,thrombocytopenia（3/24,12.5%）,nausea /vomiting（3/24,12.5%）.These toxicities were mainly related with the chemotherapy agents.Conclusion： The QOL of patients with advanced adenocarcin-oma lung cancer may be improved by endostar combined with chemotherapy.Maybe there have synergetic effects of endostar with some of cytotoxic agents.It is worthy of clinical generalization and further clinical observation.